Blosozumab
Blosozumab binds SOST, a negative regulator of osteoblast activity.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density. Blosozaumab has been studied with regard to the treatment of osteoporosis in both men and postmenopausal women.
Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect. Blosozumab was developed by Eli Lilly and Company.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1325203232 under CC BY-SA 4.0; modifications have been made.